false 0001601280 0001601280 2023-12-06 2023-12-06 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 
 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

———————

FORM 8-K

———————

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): December 6, 2023

———————

MediXall Group, Inc.

(Exact name of registrant as specified in its charter)

———————

 

Nevada 333-186282 33-0864127
(State or Other Jurisdiction (Commission (I.R.S. Employer
of Incorporation) File Number) Identification No.)

2598 E. Sunrise Blvd., Suite 2104, Fort Lauderdale, Florida 33304

(Address of Principal Executive Office) (Zip Code)

(877) 558-7750

(Registrant’s telephone number, including area code)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class Trading Symbol(s) Name of each exchange on which registered
N/A N/A N/A

 

Indicate by check mark whether the registrant is an emerging growth company as defined in in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company  ☐  

 

If an emerging growth company, indicate by checkmark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 
 

 

 
 

 

 

Item 5.02   Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

On December 6, 2023, the Board of Directors of MediXall Group, Inc. (the "Company") accepted the written resignation of Noel Guillama as its interim Principal Financial Officer and appointed Shane Glavin to replace Mr. Guillama.

 

Shane Glavin is the CEO of Power CFO. He founded Power CFO, a premier fractional CFO firm, in March 2021 to help small to mid-size companies realize the enormous financial and operational benefits that enterprise-level organizations expect and experience every day.

 

Shane is a results-driven executive with more than 20 years of experience in finance, accounting, and operations management. He has an MBA from Baker University located in Baldwin City, Kansas.

 

Prior to launching Power CFO, Shane developed the Rock and Evolve programs, both of which drove millions of dollars in savings. In 2019, Shane was recognized by both the Kansas City Business Journal and Bullhorn for his ability to identify significant operational inefficiency and gaps and quickly implement strategic technology and/or streamlining business operations, which significantly increased revenue and reduced company costs.

 

Shane has been the CFO and Chief Innovation Officer for LaborMAX Staffing and was VP Finance & Administration/Corporate Controller for Midwest Pacific Rail Net & Logistics.

  

Item 9.01   Financial Statements and Exhibits.

 

(d) Exhibits.

 

Exhibit No.   Description
     
104   Cover Page Interactive Data File (the cover page XBRL tags are embedded within the inline XBRL document)

 

 

 
 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  MediXall Group Inc.
     
     
Dated: December 12, 2023 By: /s/ Travis Jackson
  Name:

Travis Jackson

Title: Chief Executive Officer

 

 

 

 

 

 

 

v3.23.3
Cover
Dec. 06, 2023
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Dec. 06, 2023
Entity File Number 333-186282
Entity Registrant Name MediXall Group, Inc.
Entity Central Index Key 0001601280
Entity Tax Identification Number 33-0864127
Entity Incorporation, State or Country Code NV
Entity Address, Address Line One 2598 E. Sunrise Blvd.
Entity Address, Address Line Two Suite 2104
Entity Address, City or Town Fort Lauderdale
Entity Address, State or Province FL
Entity Address, Postal Zip Code 33304
City Area Code (877)
Local Phone Number 558-7750
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Emerging Growth Company false
MediXall (CE) (USOTC:MDXL)
Gráfica de Acción Histórica
De Oct 2024 a Nov 2024 Haga Click aquí para más Gráficas MediXall (CE).
MediXall (CE) (USOTC:MDXL)
Gráfica de Acción Histórica
De Nov 2023 a Nov 2024 Haga Click aquí para más Gráficas MediXall (CE).